

# Site Specific Data Items (SSDI)

Developed by Jennifer Ruhl and the  
SSDI Taskforce

**Presented March 2018 during the SEER Manager's Meeting**



# What is an SSDI

Presented March 2018 during  
the SEER Manager's Meeting

- Site-Specific Data Item
  - Based on primary site
  - AJCC Chapter
  - Summary Stage chapter
- Previously collected as Collaborative Stage Site-Specific Factors
  - Not all SSFs were converted to SSDIs
- Each SSDI applies only to selected schemas
- Additional information about the process of converting SSFs to SSDIs can be found in the SSDI manual

## ●●● 2018 Data Collection

Presented March 2018 during  
the SEER Manager's Meeting

- ALL SSFs retained for 2004-2017
- SSF requirements based on year of diagnosis NOT date case abstracted
  - Follow your standard setter's SSF requirements for the year when case diagnosed
- Example: 2017 case abstracted in 2018
  - Code the applicable/required SSFs, not the SSDIs



## 2018 Data Collection

Presented March 2018 during  
the SEER Manager's Meeting

- SSDIs go into effect for cases diagnosed 1/1/2018+
- SSDIs items cannot be coded for any cases with diagnosis date PRIOR to 1/1/2018
- **REMEMBER:** SSDIs are based on date of diagnosis, NOT date case abstracted

## ●●● General Changes Made

Presented March 2018 during  
the SEER Manager's Meeting

- Data items different lengths
- Data items can include decimal points
- Different coding conventions used to document
  - Recording of actual values, percentages, ranges
  - Recording different definitions of unknown
- “Test not done” and “Unknown if test done” combined
  - Code reads *“X not assessed or unknown if assessed”*

## ●●● Updating the SSFs to SSDIs

Presented March 2018 during  
the SEER Manager's Meeting

- Harmonize with AJCC 8<sup>th</sup> edition
  - Donna Gress: liaison between SSDI & AJCC
- Harmonize with updated CAP guidelines
  - Richard Moldwin: liaison between SSDI & CAP
  - Data items developed using CAP guidelines checklist
  - Codes and coding instructions align with CAP checklists (as much as possible)



**Presented March 2018 during the SEER Manager's Meeting**



# SSDI Manual

Presented March 2018 during  
the SEER Manager's Meeting

- Based primarily on CS Part I, Section II
- Includes:
  - Basic information about data item:
    - Item Length
    - NAACCR Item #
    - NAACCR Alternate Name (when applicable)
    - AJCC 8<sup>th</sup> edition chapter(s)
    - Description
    - Rationale

Item Length: 4

NAACCR Item #: 3883

NAACCR Alternate Name: Lymph Nodes Size

AJCC 8th Edition Chapter(s):

**Presented March 2018 during  
the SEER Manager's Meeting**

- Chapter 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
- Chapter 7: Lip and Oral Cavity
- Chapter 8: Major Salivary Glands
- Chapter 9: Nasopharynx
- Chapter 10: HPV-Mediated (p16+) Oropharyngeal Cancer
- Chapter 11: Oropharynx (p16-) and Hypopharynx
- Chapter 12: Nasal Cavity and Paranasal Sinuses
- Chapter 13: Larynx
- Chapter 14: Mucosal Melanoma of the Head and Neck
- Chapter 15: Cutaneous Squamous Cell Carcinoma of Head and Neck

### **Description**

Lymph Nodes Size records diameter of the involved regional lymph node(s) with the largest diameter of any involved regional lymph node(s). Pathological measurement takes precedence over a clinical measurement for the same node.

### **Rationale**

Lymph Nodes Size is a Registry Data Collection Variable in AJCC for several chapters. It was previously

# ●●● SSDI Manual

Presented March 2018 during  
the SEER Manager's Meeting

- Definition
- Coding Guidelines
- Additional information
- **Coding Instructions and Codes**
  - **Part of the registry software**

## ●●● Schema ID

Presented March 2018 during  
the SEER Manager's Meeting

- Derived based on primary site, histology and schema discriminator (when applicable)
- Defines the following
  - SSDIs
  - Grade ID
  - AJCC 8<sup>th</sup> edition chapter
  - EOD schema (for those collecting EOD)
  - Summary Stage chapter

**Presented March 2018 during  
the SEER Manager's Meeting**

Paragraph		Styles	
00520: Cervix	52: <a href="#">Cervix</a>	3872: LN Assessment Method Para-aortic 3873: LN Assessment Method Pelvic 3884: LN Status Femoral-Inguinal, Para-aortic, Pelvic 3874: LN Distant Assessment Method 3875: LN Distant: Mediastinal, Scalene	
00530: Corpus Carcinoma and Carcinosarcoma	53: <a href="#">Corpus Carcinoma and Carcinosarcoma</a>	3836: FIGO Stage (Corpus Carcinoma and Carcinosarcoma) 3901: Number of Positive Para-Aortic Nodes 3899: Number of Examined Para-Aortic Nodes 3902: Number of Positive Pelvic Nodes 3900: Number of Examined Pelvic Nodes 3911: Peritoneal Cytology	
00541: Corpus Sarcoma 00542: Corpus Adenosarcoma	54: <a href="#">Corpus Sarcoma</a>	3836: FIGO Stage (Corpus Sarcoma) 3836: FIGO Stage (Corpus Adenosarcoma) 3901: Number of Positive Para-Aortic Nodes 3899: Number of Examined Para-Aortic Nodes 3902: Number of Positive Pelvic Nodes 3900: Number of Examined Pelvic Nodes 3911: Peritoneal Cytology	
00551: Ovary 00552: Primary Peritoneal Carcinoma 00553: Fallopian Tube	55: <a href="#">Ovary, Fallopian Tube, and Peritoneal Carcinoma</a>	3836: FIGO Stage (Ovary, Fallopian Tube and Primary Peritoneal Carcinomas) 3818: CA-125 Pretreatment Interpretation 3921: Residual Tumor Volume Post Cytoreduction	
00558: Adnexa Uterine Other	No AJCC Chapter	No SSDIs defined for this Schema ID	

# Appendix A

## Reference Document

### Schema ID 00071: Tongue Anterior

#### Primary Site(s)/Histology(ies)

Primary Site	Histology
C020-C023, C028-C029	8000-8700, 8982, 9700-9701

AJCC Chapter 7: Lip and Oral Cavity

EOD Schema: Tongue Anterior

Summary Stage 2018 Chapter: Tongue Anterior

#### Applicable SSDIs

- NAACCR # 3831: Extranodal Extension Head and Neck Clinical
- NAACCR # 3832: Extranodal Extension Head and Neck Pathological
- NAACCR # 3883: LN Size

#### Grade Table 01:

Code	Grade Description
1	G1: Well differentiated
2	G2: Moderately differentiated
3	G3: Poorly differentiated
9	Grade cannot be assessed (GX); Unknown

#### AJCC ID 7: Lip and Oral Cavity

Histology	AJCC ID	Description
8000, 8010, 8051-8052, 8070-8072, 8074-8075, 8082-8083, 8140, 8147, 8200, 8290, 8310, 8430, 8480, 8500, 8525, 8550, 8560, 8562, 8982	7	Oral Cavity
8001-8005, 8011-8050, 8053-8060, 8073, 8076-8081, 8084-8131, 8141-8146, 8148-8191, 8201-8281, 8300, 8311-8420, 8440-8474, 8481-8490, 8501-8524, 8530-8543, 8551-8552, 8561, 8570-8700, 9700-9701	XX	Other Oral Cavity

**Presented March 2018 during  
the SEER Manager's Meeting**

# Appendix B

Presented March 2018 during the SEER Manager's Meeting

A	B	D	E	F	G	H
AJCC 7th	AJCC 7th Edition Chapter Name	SSF#	SSF Name	Status (based on CoC)	2018 NAACCR Data Item#	NAACCR Data Item Name
		25	Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct	Required	3926	Schema Discriminator 1
21	Perihilar Bile Ducts	10	Tumor Growth Pattern	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		11	Primary Sclerosing Cholangitis (PSC)	Required	3917	Primary Sclerosing Cholangitis
		12	Carbohydrate Antigen 19-9 (CA 19-9) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		13	Carcinoembryonic Antigen (CEA)	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		14	Carcinoembryonic Antigen (CEA) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		25	Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct	Required	3926	Schema Discriminator 1
22	Distal Bile Duct	12	Carbohydrate Antigen 19-9 (CA 19-9) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		13	Carcinoembryonic Antigen (CEA)	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		14	Carcinoembryonic Antigen (CEA) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		25	Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct	Required	3926	Schema Discriminator 1
23	Ampulla Vater	1	Carbohydrate Antigen 19-9 (CA 19-9) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		2	Carcinoembryonic Antigen (CEA)	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		3	Carcinoembryonic Antigen (CEA) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
24	Pancreas	1	Carbohydrate Antigen 19-9 (CA 19-9) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		2	Serum Chromogranin A (CgA) Lab Value	Discontinued	N/A	N/A (discontinued SSF CSv0204)
		3	Mitotic Count	Discontinued	N/A	N/A (discontinued SSF CSv0204)
25	Lung	1	Separate Tumor Nodules - Ipsilateral Lung	Required	3929	Separate Tumor Nodules
		2	Pleural/Elastic Layer Invasion (PL) by H and E or Elastic Stain	Required	3937	Visceral Pleural Invasion
26	Pleural	1	Pleural Effusion	Required	3913	Pleural Effusion
		2	Histologic Subtype	Required	N/A	Data item not being required for this site in 2018
		3	Watermark of Asbestos Exposure	Discontinued	N/A	N/A (discontinued SSF CSv0204)



**Presented March 2018 during the SEER Manager's Meeting**

## ●●● Schema Discriminators

- Schema discriminators introduced in 2010 (CSv2)
  - Used when primary site and/or histology are not enough to get to right schema
- Schema discriminators for 2018
  - Schema discriminator 1
  - Schema discriminator 2
  - Schema discriminator 3 (none for 2018)



# Schema Discriminators

## Schema Discriminator 1

Item Length: 1

NAACCR Item #: 3926

NAACCR Alternate Name: None

### Description

Captures additional information needed to generate AJCC ID and Schema ID for some anatomic sites. Discriminators can be based on sub site, histology or other features which affect prognosis.

### Rationale

A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and Schema ID, which links each case to the appropriate SSDIs, Summary Stage and EOD data collection system.

**Codes (The information recorded in Schema Discriminator differs for each anatomic site. See the SSDI manual for most current version of the site-specific codes and coding structures.)**

The following are Schema Discriminator 1

- [Schema Discriminator 1: BileDuctsDistal/BileDuctsPerihilar/CysticDuct](#)
- [Schema Discriminator 1: EsophagusGEJunction \(EGJ\)/Stomach](#)
- [Schema Discriminator 1 \(Histology Discriminator for 9591/3\)](#)
- [Schema Discriminator 1: Lacrimal Gland/Sac](#)
- [Schema Discriminator 1: Melanoma Ciliary Body/Melanoma Iris](#)
- [Schema Discriminator 1: Nasopharynx/Pharyngeal Tonsil](#)
- [Schema Discriminator 1: Occult Head and Neck Lymph Nodes](#)
- [Schema Discriminator 1: Plasma Cell Myeloma Terminology](#)
- [Schema Discriminator 1: Primary Peritoneum Tumor](#)
- [Schema Discriminator 1: Thyroid Gland/Thyroglossal Duct](#)
- [Schema Discriminator 1: Urethra/Prostatic Urethra](#)

**Presented March 2018 during  
the SEER Manager's Meeting**

# ●●● Schema Discriminators

Presented March 2018 during  
the SEER Manager's Meeting

Schema Discriminator	AJCC 8 <sup>th</sup> Chapter(s)	Purpose
Occult Head and Neck Lymph Nodes	6 <b>(New)</b>	Used to distinguish an unknown head and neck tumor that has positive regional nodes
Oropharyngeal p16	10, 11 <b>(New)</b>	Used to distinguish between oropharyngeal p16+ tumors and p16- tumors
Histology Discriminator for 8020/3	16 <b>(New)</b>	Histology code 8020/3 (undifferentiated carcinoma): Squamous vs glandular (adenocarcinoma) ( <i>see AJCC 8<sup>th</sup> edition, page 186</i> ) <i>Discriminator not used for any other histology</i>

# ●●● Schema Discriminators

Presented March 2018 during  
the SEER Manager's Meeting

Schema Discriminator	AJCC 8 <sup>th</sup> Chapter(s)	Purpose
Urethra/Prostatic Urethra	63 <b>(New)</b>	Used to distinguish between urethra (male and female) and prostatic urethra, both coded to primary site C680
Thyroid Gland/Thyroglossal Duct	73, 74 <b>(New)</b>	Used to distinguish between thyroid and thyroglossal duct, both coded to primary site C739 <i>Note: Thyroglossal duct tumors are not eligible for AJCC 8<sup>th</sup> edition stage</i>
Histology discriminator for 9591/3	79, 80, 83 <b>(New)</b>	Used to distinguish between different alternate terms for 9591/3. (Alternate names also included in the Hematopoietic database)



# SSDIs Required for Staging for AJCC 8<sup>th</sup> Edition

AJCC Chapter	NAACCR Data Item #	NAACCR Data Item Name	EOD Schema(s)
16: Esophagus (Squamous cell only)	3829	<a href="#">Esophagus and EGJ Tumor Epicenter</a>	Esophagus (including GE junction) Squamous
	3827	<a href="#">Estrogen Receptor Summary</a>	
48: Breast	3915	<a href="#">Progesterone Receptor Summary</a>	Breast
	3855	<a href="#">HER2 Overall Summary</a>	
	3904	<a href="#">Oncotype Dx Recurrence Score-Invasive</a>	
56: Gestational Trophoblastic Tumors (Placenta)	3837	<a href="#">Gestational Trophoblastic Prognostic Scoring Index</a>	Placenta
58: Prostate	3920	<a href="#">PSA (Prostatic Specific Antigen) Lab Value</a>	Prostate
59: Testis	3923	<a href="#">S Category Clinical</a>	Testis
	3924	<a href="#">S Category Pathological</a>	
68: Retinoblastoma	3856	<a href="#">Heritable Trait</a>	Retinoblastoma
79: Non-Hodgkin Lymphoma: CLL/SLL	3804	<a href="#">Adenopathy (Rai Classification: CLL/SLL)</a>	Lymphoma (CLL/SLL)
	3811	<a href="#">Anemia (Rai Classification: CLL/SLL)</a>	
	3885	<a href="#">Lymphocytosis (Rai Classification: CLL/SLL)</a>	
	3907	<a href="#">Organomegaly (Rai Classification: CLL/SLL)</a>	
	3933	<a href="#">Thrombocytopenia (Rai Classification: CLL/SLL)</a>	
81: Primary Cutaneous Lymphomas: Mycosis Fungoides	3910	<a href="#">Peripheral Blood Involvement</a>	Mycosis Fungoides
82: Plasma Cell Myeloma and Plasma Cell Disorders	3857	<a href="#">High Risk Cytogenetics</a>	Plasma Cell Myeloma
	3869	<a href="#">LDH Pretreatment Level</a>	
	3930	<a href="#">Serum Albumin Pretreatment Level</a>	
	3931	<a href="#">Serum Beta-2 Microglobulin Pretreatment Level</a>	

**Presented March 2018 during  
the SEER Manager's Meeting**

# Additional SSDIs required for EOD

Presented March 2018 during  
the SEER Manager's Meeting

- The following are also required in the EOD derivations

Applicable AJCC Chapter	NAACCR Data Item #	NAACCR Data Item Name	EOD Schema(s)
7: Lip and Oral Cavity	3883	<a href="#">LN Size</a>	Lip, Tongue Anterior, Gum, Floor of Mouth, Palate Hard, Buccal Mucosa, Mouth Other
10: HPV-Mediated (p16+) Oropharyngeal Cancer	3883	<a href="#">LN Size</a>	Oropharynx p16+
47: Melanoma Skin	3869	<a href="#">LDH Pretreatment Lab Value</a>	Melanoma Skin
48: Breast	3882	<a href="#">LN Positive Axillary Level I-II</a>	Breast
53: Corpus Uteri-Carcinoma and Carcinosarcoma	3911	<a href="#">Peritoneal Cytology</a>	Corpus Carcinoma and Carcinosarcoma
54: Corpus Sarcoma	3911	<a href="#">Peritoneal Cytology</a>	Corpus Adenosarcoma and Corpus Sarcoma
67: Uveal Melanoma	3887	<a href="#">Measured Basal Diameter</a>	Melanoma Choroid and Ciliary Body; Melanoma Iris
	3888	<a href="#">Measured Thickness</a>	

## ●●● Lab Values and Percentages

Presented March 2018 during  
the SEER Manager's Meeting

- New format adopted
- Decimal points included
- Length of data item dependent on highest value recommended by AJCC 8<sup>th</sup> edition
- Values for “not applicable” and “unknown” differ based on length of data item
  - Not applicable codes ALWAYS end in ‘8’
  - Unknown codes ALWAYS end in ‘9’

# ●●● Prostate, SSF #1: Prostatic Specific Antigen (PSA)

## Lab Value

Presented March 2018 during the SEER Manager's Meeting

Code	Description
000	OBSOLETE DATA CONVERTED V0200 See code 998  Test not done (test was not ordered and was not performed)
001	0.1 or less nanograms/milliliter (ng/ml) (Exact value to nearest tenth of ng/ml)
002-979	0.2 - 97.9 ng/ml (Exact value to nearest tenth of ng/ml)
980	98.0 ng/ml or greater
981-987	OBSOLETE DATA CONVERTED V0200 See code 980  98.1 - 98.7 ng/ml

# ●●● PSA (Prostatic Specific Antigen) Lab Value (#3920)

Presented March 2018 during the SEER Manager's Meeting

Code	Description
0.1	0.1 or less nanograms/milliliter (ng/ml) (Exact value to nearest tenth of ng/ml)
0.2-999.9	0.2 – 999.9 ng/ml (Exact value to nearest tenth of ng/ml)
XXX.1	1,000 ng/ml or greater
XXX.7	Test ordered, results not in chart
XXX.9	Not documented in medical record PSA lab value not assessed or unknown if assessed

**Examples:**

**PSA of 5.4**

**Enter 5.4**

**PSA 125**

**Enter 125.0**

**PSA Unknown**

**Enter XXX.9**

**Note 1: Do not have to enter leading zeroes for values less than 100.0**

**Note 2: Code XXX.9 includes test not done or unknown if test done**

# ●●● Colon, SSF #3: Carcinoembryonic Antigen (CEA) Lab Value

Presented March 2018 during the SEER Manager's Meeting

Code	Description
000	0.0 nanograms/milliliter (ng/ml) exactly
001	0.1 or less ng/ml Stated as less than 0.1 ng/ml with no exact value
002-979	0.2-97.9 ng/ml (Exact value to nearest tenth in ng/ml)
980	98.0 or greater ng/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSV1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test not ordered and not performed)
999	Unknown or no information Not documented in patient record

# ●●● CEA Pretreatment Lab Value (#3820)

Presented March 2018 during  
the SEER Manager's Meeting

Code	Description
0.0	0.0 nanograms/milliliter (ng/ml) exactly
0.1	0.1 or less ng/ml Stated as less than 0.1 ng/ml with no exact value
0.2- 9999.9	0.2-9999.9 ng/ml (Exact value to nearest tenth in ng/ml)
XXXX.1	10,000.0 ng/ml or greater
XXXX.7	Test ordered, results not in chart
XXXX.8	Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code XXXX.8 may result in an edit error.)
XXXX.9	Not documented in medical record CEA (Carcinoembryonic Antigen) Pretreatment Lab Value not assessed or unknown if assessed

**Examples:**

**CEA of 5.4**

**Enter 5.4**

**CEA 1254.3**

**Enter 1254.3**

**CEA Unknown**

**Enter XXXX.9**

**Note 1: Do not have to enter leading zeroes for values less than 1000.0**

**Note 2: Codes XXXX.8 used for when your standard setter does not require data item**

**Note 2: Code XXXX.9 includes test not done or unknown if test done**

# ●●● Lacrimal Gland, SSF #6: Adenoid Cystic Carcinoma-Presence of Basaloid Pattern

Presented March 2018 during the SEER Manager's Meeting

Code	Description
000	Basaloid pattern not present in adenoid cystic carcinoma
010	Basaloid pattern present in adenoid cystic carcinoma
020	OBSOLETE DATA CONVERTED V0203 See code 000  Basaloid pattern not present in adenoid cystic carcinoma
888	OBSOLETE DATA CONVERTED V0200 See code 988  Not applicable for this site
987	Not applicable, histology not adenoid cystic carcinoma
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSV1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
998	No pathologic examination of primary site
999	Unknown or no information Not documented in patient record

# ●●● Adenoid Cystic Basaloid Pattern (#3803)

Presented March 2018 during  
the SEER Manager's Meeting

Code	Description
0.0-100.0	0.0 to 100.0 percent basaloid pattern
XXX.5	Basaloid pattern present, percentage not stated
XXX.6	Not applicable, histology not adenoid cystic carcinoma (8200/3)
XXX.8	Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)
XXX.9	Not documented in medical record Adenoid Cystic Basaloid Pattern not assessed or unknown if assessed

## ●●● Other Data Items

Presented March 2018 during  
the SEER Manager's Meeting

- Majority 1-2 digits long
- Do not include lab values, percentages or some other type of measurement
- No decimal points
- Very similar to the CS data item-except for length of data item

# ●●● Colon and Rectum, SSF #8: Perineural Invasion

Presented March 2018 during the SEER Manager's Meeting

Code	Description
000	None; no perineural invasion present
010	Perineural invasion present
988	Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 988 may result in an edit error.)
998	No histologic examination of primary site
999	Unknown Not documented in patient record

# ●●● Perineural Invasion (#3909)

Presented March 2018 during  
the SEER Manager's Meeting

Code	Description
0	Perineural invasion not identified/not present
1	Perineural invasion identified/present
8	Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 8 may result in an edit error.)
9	Not documented in medical record Pathology report does not mention perineural invasion Cannot be determined by the pathologist Perineural invasion not assessed or unknown if assessed

**Note: If there is no mention of perineural invasion, must code 9. In CS, if there was no mention of perineural invasion, none could be coded. This applies to several data items and is noted in the SSDI manual**

# ●●● Corpus Carcinoma, SSF #3: Number of Positive Pelvic Nodes

Presented March 2018 during the SEER Manager's Meeting

Code	Description
000	All pelvic nodes examined negative.
001-089	1 - 89 pelvic nodes positive (Exact number of nodes positive)
090	90 or more pelvic nodes positive
095	Positive aspiration or core biopsy of pelvic lymph node(s)
097	Positive pelvic nodes, number not specified
098	No pelvic nodes examined
888	OBSOLETE DATA CONVERTED V0200 See code 988  Not applicable for this site
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
999	Unknown if pelvic nodes are positive Not documented in patient record

# ●●● Number of Positive Pelvic Nodes (#3902)

Presented March 2018 during the SEER Manager's Meeting

Code	Description
00	All pelvic nodes examined negative
01-99	1 - 99 pelvic nodes positive (Exact number of nodes positive)
X1	100 or more pelvic nodes positive
X2	Positive pelvic nodes identified, number unknown
X6	Positive aspiration or core biopsy of pelvic lymph node(s)
X8	Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code X8 will result in an edit error.)
X9	Not documented in medical record Cannot be determined, indeterminate if positive pelvic nodes present Pelvic lymph nodes not assessed or unknown if assessed



**The Grade Manual**

**Presented March 2018 during the SEER Manager's Meeting**



## Grade

Presented March 2018 during  
the SEER Manager's Meeting

- Standard Grade data item discontinued, retained for cases diagnosed prior to 1/1/2018
- Current SSFs that collect chapter specific grades (e.g., Breast, Prostate, Soft Tissue, Appendix) discontinued, retained for cases 2004-2017



# Grade Manual Set Up

Presented March 2018 during  
the SEER Manager's Meeting

- Introduction
  - General Instructions
  - General Rules
- Grade Tables
  - Each set of grade tables has clinical, pathological and post-therapy, along with coding instructions
- Registry software will include the relevant grade table and coding instructions



## New Grade Data Items

Presented March 2018 during  
the SEER Manager's Meeting

- Grade Clinical
  - Grade collected during clinical time frame
- Grade Pathological
  - Grade collected after resection without neoadjuvant therapy
- Grade Post-therapy
  - Grade collected after resection following neoadjuvant therapy



## Grade

Presented March 2018 during  
the SEER Manager's Meeting

- Grade coding instructions from 2014 will no longer be used for cases diagnosed 1/1/2018+
  - Still applicable for cases diagnosed 2014-2017
- Grade coding instructions, codes and code descriptions will be site specific

## ●●● Grade

Presented March 2018 during  
the SEER Manager's Meeting

- New grade data items will
  - Incorporate chapter specific grading systems (when applicable)
    - May be 2, 3, or 4 grade system
    - No longer need to convert to 4 grade system
  - Allow for coding of grade at different points of patient care
  - Historical definitions used when specific grading systems not available or not applicable



# Grade-Breast

Presented March 2018 during  
the SEER Manager's Meeting

G	G Definition
1	G1: Low combined histologic grade (favorable), SBR score of 3–5 points
2	G2: Intermediate combined histologic grade (moderately favorable); SBR score of 6–7 points
3	G3: High combined histologic grade (unfavorable); SBR score of 8–9 points
L	Nuclear Grade I (Low) (in situ only)
M	Nuclear Grade II ( <u>interMediate</u> ) (in situ only)
H	Nuclear Grade III (High) (in situ only)
A	Well differentiated
B	Moderately differentiated
C	Poorly differentiated
D	Undifferentiated, anaplastic
9	Grade cannot be assessed (GX); Unknown Not applicable

## ●●● Grade

Presented March 2018 during  
the SEER Manager's Meeting

- New grade table now used for AJCC chapters that have no grading system listed AND for those primary site/histologies combinations not covered in 8<sup>th</sup> edition

<b>Code</b>	<b>Grade/Cell Type Description</b>
A	Well differentiated
B	Moderately differentiated
C	Poorly differentiated
D	Undifferentiated, anaplastic
9	Grade cannot be assessed; Unknown



**Presented March 2018 during the SEER Manager's Meeting**

## ●●● Points to remember

Presented March 2018 during  
the SEER Manager's Meeting

- Majority of SSDIs were SSFs
- Most changes are to length of data items and decimal points allowed for applicable data items
- Most new data items are needed for AJCC 8<sup>th</sup> edition stage

# ●●● SSDI Manual and Grade Manual

Presented March 2018 during  
the SEER Manager's Meeting

- Questions/comment/suggestions regarding Manual are to be posted in the CAnswer Forum
  - <http://cancerbulletin.facs.org/forums/forum/site-specific-data-items-grade-2018>

Thank You!